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Abstract The syndrome Multiple Congenital Ocular
Anomalies (MCOA) is the collective name ascribed to
heritable congenital eye defects in horses. Individuals
homozygous for the disease allele (MCOA phenotype)
have a wide range of eye anomalies, while heterozygous
horses (Cyst phenotype) predominantly have cysts that
originate from the temporal ciliary body, iris, and/or
peripheral retina. MCOA syndrome is highly prevalent in
the Rocky Mountain Horse but the disease is not limited to
this breed. Affected horses most often have a Silver coat
color; however, a pleiotropic link between these pheno-
types is yet to be proven. Locating and possibly isolating
these traits would provide invaluable knowledge to scien-
tists and breeders. This would favor maintenance of a
desirable coat color while addressing the health concerns of
the affected breeds, and would also provide insight into the
genetic basis of the disease. Identical-by-descent mapping
was used to narrow the previous 4.6-Mb region to a 264-kb
interval for the MCOA locus. One haplotype common to
four breeds showed complete association to the disease
(Cyst phenotype, n = 246; MCOA phenotype, n = 83).
Candidate genes from the interval, SMARCC2 and IKZF4,
were screened for polymorphisms and genotyped, and
segregation analysis allowed the MCOA syndrome region
to be shortened to 208 kb. This interval also harbors
PMEL17, the gene causative for Silver coat color. How-
ever, by shortening the MCOA locus by a factor of 20, 176
other genes have been unlinked from the disease and only
15 genes remain.
Introduction
Multiple Congenital Ocular Anomalies (MCOA) syndrome
is a congenital nonprogressive syndrome described in
horses. The most frequent feature of this disease is ﬂuid-
ﬁlled cysts of variable sizes (2–20 mm) in the posterior iris
and ciliary body epithelium within the eye. Two distinct
ocular phenotypes exist: (1) cysts that originate from the
posterior iris, temporal ciliary body, and/or peripheral ret-
ina (Cyst phenotype), and (2) cysts in combination with
additional ocular defects including iridocorneal angle
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tal cataracts, lens subluxation, focal areas of retinal
detachment, microphthalmia, and macropalpebral ﬁssures
(MCOA phenotype). Horses with MCOA have abnormal
pupillary light reﬂexes and pupils do not dilate after
administration of mydriatic drugs (Ramsey et al. 1999a, b).
Individual MCOA-affected horses may or may not have the
complete set of congenital defects described above. Both
the distinct subdivision of phenotypes and the transmission
of the disease within our pedigrees are consistent with a
mutant allele displaying incomplete dominance. The Cyst
horses are heterozygous and have an intermediate pheno-
type compared to the horses with multiple anomalies that
carry two copies of the disease allele (Ewart et al. 2000;
Andersson et al. 2008).
Conditions have been favorable for the mutation causing
MCOA to be enriched in the Rocky Mountain Horse breed
(Ewart et al. 2000). This breed originated from a very lim-
ited number of founder horses, which were used extensively
to develop the breed. In fact, many Rocky Mountain horses
canbetracedbacktoasinglefoundationstallion.Thehorses
within the breed have been selected for a distinctive four-
beat gait and the Silver coat color has been highly favored.
The fact that an intensive selection process can lead to
ampliﬁcation of undesirable traits has been demonstrated in
several other horse breeds [e.g., hyperkalemic periodic
paralysis (Rudolph et al. 1992), hereditary equine regional
dermal asthenia (Tryon et al. 2007), severe combined
immunodeﬁciency (Shin et al. 1997), and Overo Lethal
White Syndrome (Santschi et al. 1998)]. In the Rocky
Mountain Horse breed, selection of horses with the highly
desirable Silver coat color has simultaneously increased
MCOA syndrome as these traits are linked on horse chro-
mosome 6 (Andersson et al. 2008). The Silver coat color in
horses is characterized by dilution of black pigment in the
hair and revealed to be associated with a missense mutation
in pre-melanosomal protein 17 or PMEL17 (Brunberg et al.
2006). Additional horse breeds that have been diagnosed
with MCOA include the Kentucky Mountain Saddle Horse,
Mountain Pleasure Horse (both closely related to the Rocky
Mountain Horse), Belgian Draft, Morgan Horse, Shetland
Pony, American Miniature Horse (Ramsey et al. 1999a;
Grahn et al. 2008; Komaromy and Rowlan 2009), and the
Icelandic Horse (B. Ekesten, unpublished).
Cysts are found in most affected horses and are usually
bilateral. Horses with cysts usually have normal functional
vision irrespective of cyst size since cysts are either
translucent or lightly pigmented. A small number of
juvenile horses that have cornea globosa as a component of
multiple ocular defects have a considerable refractive error
and subsequently poor vision. This refractive error is cor-
rected by emmetropization as the juvenile horse eye
achieves adult size (Ramsey et al. 2000).
The primary objective of this research was to identify
the gene and mutation that regulate the MCOA syndrome
in horses. The results would have practical implications
such as enable genetic testing for precise diagnosis of
carrier horses and horses with the multiple eye defects.
We previously mapped the locus for equine MCOA to a
4.9-Mb interval on horse chromosome 6 by linkage map-
ping (Andersson et al. 2008). In the present study we have
signiﬁcantly limited the interval for the MCOA locus and
selected two additional candidate genes in the interval,
IKZF4 and SMARCC2, for mutation screening. IKZF4 was
selected as a candidate gene because it is expressed in
ocular tissue, is a member of the IKAROS family of
transcription factors, and interacts with the gene micro-
phthalmia-associated transcription factor, MITF (Hu et al.
2007). MITF inﬂuences both pigmentation and ocular
development (Hodgkinson et al. 1993). Mutations in MITF
can cause Waardenburg syndrome type 2A (Nobukuni
et al. 1996), an auditory-pigmentary disorder that affects
ocular development. In addition, a mutation in the PAX3
gene causes Waardenburg syndrome type 1, and it has been
suggested that it occurs through a failure to regulate MITF
(Watanabe et al. 1998). The other candidate gene,
SMARCC2, was selected because it encodes a 170-kDa
protein that is one of 12 proteins in the SWI/SNF complex
(Dechassa et al. 2008). The ATPase component Brm of this
complex regulates differentiation of early retinal stem cells
(Das et al. 2007). In humans, the SWI/SNF chromatin
remodeling complex is involved in the regulation of the
CRYAB (ab-crystallin) gene that is highly expressed in the
vertebrate lens where cataracts are commonly associated
with crystalline protein deﬁciencies (Liu et al. 2001;
Duncan and Zhao 2007). The present study deﬁnes a
208-kb genomic interval for the MCOA locus by identical-
by-descent (IBD) mapping of multiple horse breeds.
Materials and methods
Horse material
Four hundred sixty-ﬁve horses were genotyped in this study
(Table 1), including 362 Rocky Mountain horses, 57
American Miniature horses, 22 Kentucky Mountain Saddle
horses, and 24 Icelandic horses. All Rocky Mountain horses
evaluated in this study were derived from four half-sibling
families and have been described previously (Ewart et al.
2000). The distributions for phenotypes of Rocky Mountain
horses were 72 with MCOA, 222 with Cyst phenotype, and
68 unaffected horses. Distribution of phenotypes for the
remaining breeds was as follows: American Miniature
Horse: 3 MCOA, 14 Cyst, 40 unaffected; Kentucky
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and Icelandic Horse: 4 MCOA, 14 Cyst, 6 unaffected.
Phenotype assessment
Eye examinations were performed as described previously
(Ramsey et al. 1999a). Brieﬂy, direct and indirect pupillary
light reﬂexes were ﬁrst assessed. Following pharmacologic
mydriasis with 1% tropicamide administered topically, a
complete ophthalmic examination consisting of slit lamp
biomicroscopy, indirect ophthalmoscopy, and applanation
tonometry was performed. The study was approved by the
Michigan State University Institutional Animal Use and
Care Ethics Committee for all breeds except the Icelandic
Horse; for that breed, the study was approved by the Ethics
Committee for Animal Experiments in Uppsala, Sweden.
Microsatellite genotyping
Fourteen microsatellite markers spanning approximately
12 Mb on ECA6q were used for genotyping (Table 2,
Supplementary File 1). Seven of these markers were
identiﬁed previously (TKY570, TKY412, TKY284, UPP5,
UPP6, UPP7, and TKY952), while seven were novel and
developed from the horse genome sequence (EquCab2)
(UCSC Genome Browser, http://genome.ucsc.edu/)b y
displaying tracks from simple tandem repeats recognized
by Tandem Repeats Finder (Benson 1999). Initially,
genotyping was done on a limited number of horses for a
wide interval. Subsequently, an increased number of
horses were genotyped for a smaller region that was
approximately 2–3 Mb wide. After identifying recombinant
horses, further marker genotyping focused on these sam-
ples. Table 2 summarizes the number of horses that were
genotyped for each marker. Primers for novel microsatel-
lites were designed using Primer3 (Rozen and Skaletsky
2000). PCR reactions were performed as described previ-
ously (Andersson et al. 2008). Ampliﬁed fragments were
multiplexed when possible and separated using a Mega-
BACE
TM 1000 instrument (GE Healthcare Bio-Science
Corp., Piscataway, NJ) according to the manufacturer’s
recommendations. Results were analyzed using Genetic
Proﬁler ver. 2.4 (Amersham Bioscience, GE Healthcare
Bio-Science Corp.). Parentage testing was performed
according to standard procedures (17 microsatellite mark-
ers, Equine Genotypes
TM Panel 1.1, Finnzymes Oy, Espoo,
Finland) at the Animal Genetics Laboratory, Swedish
University of Agricultural Sciences, Uppsala.
SNP genotyping
Six single nucleotide polymorphism (SNP) markers were
selected in regions lacking microsatellite markers. Custom
TaqMan SNP Genotyping assays [Applied Biosystems
(ABI), Foster City, CA] were used for genotyping ﬁve of
the SNPs. Probe and primer designs were obtained from the
ABI web page (http://www5.appliedbiosystems.com/tools/
cadt/) using the custom genotyping assays order option.
The ABI PRISM 7900 HT sequence detection system for
384-well format (ABI) was used for the analysis. The six
selected SNP markers were genotyped in 123–465 horses
(Table 2). One additional SNP was investigated in 33
horses by traditional Sanger sequencing (see the next
subsection). The PMEL17 SNP in exon 11 was interrogated
using pyrosequencing as described previously (Andersson
et al. 2008).
Sanger sequencing of SMARCC2 and IKZF4
Two candidate genes, SMARCC2 and IKZF4, within the
identiﬁed genomic interval were sequenced using the
Sanger method. Three horses with MCOA and two unaf-
fected controls were used to sequence SMARCC2, while
two MCOA horses and one unaffected control were used
for sequencing IKZF4. The generated DNA sequences
were also compared with the horse reference genome
(Wade et al. 2009). Since none of the genes are well
annotated in the horse genome, exon number, size, and
position were deduced by displaying the track ‘‘None-
Horse mRNA’’ from GenBank. Sequencing primers were
designed to amplify 500–700-bp fragments using Primer3
(Rozen and Skaletsky 2000). Primer sequences are listed in
Supplementary File 1. All exons, as well as some introns,
the untranslated regions (UTRs), and certain evolutionary
Table 1 Number of horses investigated in the present study
Breed MCOA phenotype Cyst phenotype Unaffected Unaffected (Silver) Total
Rocky Mountain Horse 72 222 59 9 362
Kentucky Saddle Horse 4 4 13 1 22
American Miniature Horse 3 14 37 3 57
Icelandic Horse 4 14 3 3 24
Total 83 254 112 16 465
The unaffected horses that are Silver represent the nonpenetrance horses in this study
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1). Sequencing reactions were carried out as described
previously (Brunberg et al. 2006) and results were analyzed
using CodonCode software (CodonCode Aligner ver.
1.6.3, CodonCode Corporation, Dedham, MA). Consensus
sequences were deposited in GenBank (accession Nos.
HQ331540 and HQ331541 for SMARCC2 and IKZF4,
respectively).
Results
Haplotype analysis
Genotyping of 14 microsatellite and 7 SNP markers ﬁrmly
identiﬁed a 264-kb genomic interval for the MCOA locus
(Tables 2, 3 haplotype A, B, C1, and D1). SNP markers N1
and 8453 represented the 50 and 30 borders of the interval,
respectively. Four of the microsatellite markers (MS14,
MS3, TKY284, and MS13) and three SNPs (PMEL17ex11,
8345, and 8377) reside within the interval. Table 2 displays
the results from the genotyping of each marker. With the
exception of markers PMEL17 and TKY284, disease-asso-
ciated alleles are also common in unaffected horses. Phased
data of chromosomes that carry the mutation is depicted in
Table 3. Forty-eight percent of the individual genotypes
were inferred based on surrounding marker information.
This was performed only when the haplotype could be
assessed with certainty. In total, a combination of 457
affected and unaffected horses of four breeds were used to
deﬁne the interval (see schematic ﬁgure in Supplementary
File 2). This corresponds to 409 analyzed chromosomes
that carry the MCOA mutation (including horses with both
the MCOA and the Cyst phenotype). Of 83 MCOA horses
included in this study, 81 were homozygous for the dis-
ease-associated haplotype; the remaining two horses were
diagnosed clinically with MCOA but carried only one copy
of the disease haplotype. Of the 254 horses with the Cyst
phenotype, 245 were heterozygous for the disease-associ-
ated haplotype and one horse had two copies of the disease
haplotype. The remaining eight horses had individually
unique haplotypes (see Supplementary File 2). These
horses were parentage-tested to determine whether DNA
and/or blood sample error had occurred. However, par-
entage results were accurate. Our genetic data also revealed
16 horses in which the Cyst genotype showed nonpente-
trance. These horses represent only 6% of all genetically
deﬁned heterozygous horses.
Table 2 Genotyping results for 21 markers among horses grouped according to phenotypic status
Position Marker Total MCOA Cyst Unaffected
nn f (MM) f (Mm) f (mm) nf (MM) f (Mm) f (mm) nf (MM) f (Mm) f (mm)
66793555 TKY570 82 26 0.31 0.62 0.08 35 0.11 0.57 0.31 21 0.00 0.43 0.57
70589359 TKY412 178 41 0.29 0.44 0.27 105 0.03 0.43 0.54 26 0.00 0.04 0.96
72902566 MS18 433 74 0.27 0.39 0.34 231 0.02 0.46 0.52 120 0.01 0.19 0.80
73607795 MS1 434 75 0.85 0.13 0.01 231 0.22 0.71 0.08 120 0.03 0.27 0.71
73640494 N1 33 18 0.78 0.22 0.00 3 0.00 1.00 0.00 12 0.83 0.17 0.00
73658168 MS14 428 79 0.97 0.03 0.00 230 0.45 0.55 0.00 114 0.26 0.40 0.33
73665305 Pmel17-ex11 462 83 0.98 0.02 0.00 245 0.00 1.00 0.00 125 0.00 0.13 0.87
73722621 MS3 453 83 0.98 0.02 0.00 238 0.08 0.92 0.00 124 0.02 0.25 0.73
73726092 8345 135 34 0.97 0.03 0.00 30 0.43 0.57 0.00 52 0.37 0.48 0.15
73768488 TKY284 365 64 0.97 0.03 0.00 189 0.06 0.94 0.00 105 0.00 0.15 0.85
73788011 8377 129 32 0.97 0.03 0.00 40 0.70 0.30 0.00 50 0.64 0.32 0.04
73835084 MS13 447 77 0.97 0.03 0.00 234 0.03 0.97 0.00 124 0.01 0.15 0.85
73904952 8453 123 31 0.65 0.29 0.06 39 0.03 0.56 0.41 50 0.10 0.56 0.34
73968182 8475 130 33 0.67 0.27 0.06 45 0.02 0.60 0.38 49 0.00 0.24 0.76
74029118 MS21 392 71 0.82 0.14 0.04 198 0.37 0.57 0.06 115 0.19 0.51 0.30
74063248 4963 123 32 0.66 0.28 0.06 34 0.03 0.56 0.41 50 0.10 0.56 0.34
74667009 UPP6 422 71 0.86 0.14 0.00 228 0.02 0.91 0.07 115 0.00 0.10 0.90
75475234 UPP7 340 69 0.93 0.07 0.00 209 0.24 0.75 0.01 54 0.15 0.43 0.43
76228564 UPP8 184 46 0.85 0.15 0.00 101 0.06 0.89 0.05 37 0.00 0.16 0.84
78856446 MS4 91 32 0.66 0.31 0.03 36 0.50 0.44 0.06 23 0.61 0.35 0.04
79472875 TKY952 83 26 0.58 0.42 0.00 36 0.11 0.61 0.28 21 0.05 0.29 0.67
The 264-kb associated haplotype is marked in bold. The disease allele is depicted as M and an alternative allele as m. Sixteen nonpenetrance
horses are included as unaffected individuals
356 L. S. Andersson et al.: Equine MCOA locus
123Sanger sequencing of IKZF4 and SMARCC2
In total, 13.6 kb of IKZF4 (87%) were evaluated for
polymorphisms, including all exons and conserved
sequences within introns and 3.6 kb upstream of the gene
(Supplementary File 1). Comparison among MCOA horses
and unaffected control horses revealed three intronic
polymorphic sites (Supplementary File 3). Two of these
were SNPs (introns 3 and 4) and not completely associated
with the disease. The third polymorphism was a homozy-
gous adenine insertion (intron 5) in both MCOA horses that
was not present in either of the unaffected controls or the
reference genome.
Resequencing of the SMARCC2 gene covered 12.6 kb
(76%) and included all 29 exons (Supplementary File 1)
and intronic conserved elements. Ten SNPs were detected
and two of them were positioned within coding regions
(Supplementary File 3). Only two SNPs, in intron 19 and
24, respectively, matched the correct mode of inheritance
in the horses selected for resequencing. Since SMARCC2 is
positioned close to the 30 downstream border of the 264-kb
IBD interval, the intron 19 SNP was genotyped in recom-
binant horses. These are the horses with the shortest IBD
region compared with the majority of horses (Table 3,
haplotypes B-D). The disease-associated allele for this SNP
is G, but genotyping revealed nine genetically well-deﬁned
Cyst horses as being TT (Table 3, haplotypes C2 and D2).
Two additional American Miniature horses displaying the
Cyst phenotype can be phased as either C1 or C2 but have
been labeled as C2 due to a close relatedness to the other
horses carrying the C2 haplotype. Furthermore, a subset of
horses, including the newly identiﬁed recombinants, was
also genotyped for the SNP in intron 24. SMARCC2 is
positioned on the minus strand and hence intron 24 is
upstream of intron 19 according to the depicted interval.
The disease-associated allele for this SNP is also guanine
but the C2 haplotype holds an adenine at this position.
These horses thus shortened the genetic interval by 57 kb,
providing a minimum shared haplotype of 208 kb.
Discussion
Identical-by-descent mapping was used to ﬁrmly deﬁne a
208-kb genomic interval on horse chromosome 6 for the
MCOA locus. This has shortened the previous 4.9-Mb
MCOA genetic interval by a factor of 20, which has
unlinked 176 other genes from the disease. In addition, a
large number of horses were utilized to verify that the
mutation causing MCOA syndrome does have a clear
additive effect and that the two distinct phenotypic cate-
gories, Cyst and MCOA, are caused by one and two copies
of the mutant allele, respectively (p = 2.2 9 10
-16).
Results of the study reported here are based on analysis of
21 genetic markers in 465 horses from four different
breeds. The identiﬁed interval is a gene-dense area of the
genome and includes 15 genes (see Supplementary File 4).
Based on information on gene function from studies in
other species, two candidate genes within the interval,
SMARCC2 and IKZF4, were evaluated for DNA poly-
morphisms using Sanger sequencing. Two intronic SNPs
that segregated with the disease phenotype were detected in
SMARCC2. After analysis of these SNPs in recombinant
horses, the interval for the MCOA syndrome was shortened
by 57 kb (from 265 to 208 kb). Sequencing also revealed
one disease-associated insertion in intron 5 of IKZF4.
However, since this polymorphism resides within a non-
coding region, it is less likely than the PMEL17 mutation to
have a phenotypic consequence. Nevertheless, this variant
will be tested in a larger number of horses.
Table 3 Phased data of 13 markers
Haplotype No.
of Chr
MS1 N1 MS14 PMEL17-
ex11
MS3 8345 TKY284 8377 MS13 SMARCC-
int24
SMARCC-
int19
8453 8475 Breed
A 355 269 T 247 T 233 C 177/175 C 222 G G A T RH, KY
B 12 263 G 247 T 233 C 177 C 222 G G G A RH, KY
C.1 10 263 G 247 T 233 C 177 C 222 G G A A MINI
D.1 21 263 G 247 T 231 C 177 C 222 G G GAI S
D.2 1 263 G 247 T 231 C 177 C 222 G T GAI S
C.2 10 263 G 247 T 233 C 177 C 222 A T G A MINI
Position
a 0 33 50 58 115 118 161 180 227 240 242 297 360
Six haplotypes were identiﬁed in the four analyzed breeds. The number of chromosomes (Chr) and the respective breed are listed for each
haplotype. The 264-kb associated haplotype is marked in italics, while the 208-kb haplotype that includes the horses recombinant at the
SMARCC2 locus is marked in bold
a The chromosome position of marker MS1 is 73607795 and is here set as the reference point zero (0). The distance to the following markers are
given in kilobases
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A missense mutation in this gene is most likely causative of
the Silver coat color and this mutation may have pleio-
tropic effects. The protein PMEL17 is involved in the
production of eumelanin, but its precise function remains
unknown (Theos et al. 2005). Mutations within this gene
are associated with dilution of eumelanin in several spe-
cies, including mouse, chicken, zebraﬁsh, dog, cow, and
horse (Kwon et al. 1995; Kerje et al. 2004; Schonthaler
et al. 2005; Clark et al. 2006; Brunberg et al. 2006; Kuehn
and Weikard 2007). The different species vary in the type
and the location of the mutation they exhibit, although
several mutations reside near the C-terminal portion of the
protein.
To date, ocular defects associated with known PMEL17
mutants have been reported in zebraﬁsh and dog (Schont-
haler et al. 2005; Clark et al. 2006), which supports
PMEL17 as a candidate gene for MCOA syndrome in
horses. Conversely, eye defects in these species appear
dissimilar, although they are not so easily compared. In
zebraﬁsh fdv mutant larvae, the retinal pigment epithelium
(RPE) melanosome biogenesis is impaired, leading to
photoreceptors with fewer, shorter, and misaligned outer
segments. The retina is partially recovered in the adult fdv
zebraﬁsh. The zebraﬁsh RPE melanosomes have an aber-
rant shape and contain less melanin, giving the eye and the
body a lighter appearance. Merle dogs that are homozygous
for the proposed SILV mutation exhibit several different
aberrant eye phenotypes such as starburst/irregular dropped
pupils, heterochromia, and microphthalmia. Like the
zebraﬁsh, affected dogs have defects in the pigmentation
of skin, coat, and RPE.
Recently, chickens homozygous for the Dominant white
mutation, a 6-bp insertion (ins723–725) within the trans-
membrane region of PMEL17, were found to be free from
ocular abnormalities and visual impairment (Karlsson et al.
2009). Dominant white mutant chickens appeared less
pigmented than wild-type chickens in the outer layers of
the retina, but the RPE seemed to be unaltered. Further
investigations of eyes of chickens that carry the Dun allele
would be helpful since they have the exact same missense
mutation (R740C) as the horse and also have a 12-bp
deletion (del731–735).
The degree of ocular pigmentation and MCOA are
poorly correlated. All but eight horses, diagnosed with
MCOA syndrome, carried the Silver mutation, however
their RPE appears to be unaltered (Ramsey et al. 1999a;
B. Ekesten, unpublished). Pigmented uveal tissues (iris,
ciliary body, choroid) may also be darkly pigmented or
lightly pigmented in both MCOA-affected and normal
horses. Nevertheless, the fact that the MCOA syndrome has
been diagnosed in all breeds where the Silver coat color is
present favors PMEL17 as a candidate gene.
Several other possible candidate genes exist in the
interval evaluated. According to AceView, a database that
gathers all cDNA sequences available in public databases,
14 of 15 genes in the associated interval are variably
expressed in ocular tissues (Thierry-Mieg and Thierry-
Mieg 2006). A similar search in the Mouse Gene Expres-
sion Database (http://www.informatics.jax.org/expression.
shtml) showed that six of the genes were known to be
expressed in ocular tissues. To date, the remaining genes
were either not found (six genes) or there was no evidence
of expression (three genes). In addition to PMEL17,
IKZF4, and SMARCC2, a literature search identiﬁed four
other genes within the interval, SUOX, CDK2, ErbB3, and
RAB5B, that have documented connection to eye devel-
opment or function. Mutations in SUOX can cause Isolated
sulﬁte oxidase deﬁciency, a severe autosomal recessive
neurological disorder. One symptom of this disease is
dislocation of the ocular lenses (Johnson et al. 2002). The
role of the cell cycle protein CDK2 has been studied
extensively during cell differentiation and proliferation in
the lens (Wang et al. 2005). ErbB3 is a member of the
epidermal growth factor receptor family and activates a
pathway leading to cell proliferation and differentiation.
Expression of ErbB3 in conjunctiva has been shown to be
higher in patients suffering from keratoconjunctivitis sicca
(dry eye syndrome) compared with normal subjects (Liu
et al. 2000). Although direct evidence for a role of RAB5B
in ocular development was not established, several other
Rab and Rab-associated proteins are known to be involved.
Mutations in some of these genes are responsible for the
heritable eye defects choroideremia, Warburg Micro syn-
drome, and Martsolf syndrome (Corbeel and Freson 2008).
In the present study, 16 horses had clinically normal
eyes but were heterozygous for the disease haplotype
(including the PMEL17 mutation). Twelve of these had the
Silver coat color and four were chestnuts. This nonpene-
trance could be explained by genetic background or, more
likely, that very small cysts located on the posterior iris or
peripheral ciliary body may not have been detected. Con-
versely, eight horses that had the Cyst phenotype but not
the disease-associated haplotype were also identiﬁed.
However, it is conceivable that these cysts may be attrib-
utable to postinﬂammatory ocular disease or other nonhe-
reditary causes.
Results of this study are of great importance for veter-
inarians and horse breeders since genetic markers within
our identiﬁed interval (e.g., PMEL17 mutation) can be used
for genetic testing of horses. Genetic information could be
used for diagnosis of MCOA and to advise horse breeders
regarding selection of horses for breeding. Horses that are
homozygous for the disease-causing alleles exhibit the
most severe clinical signs. Therefore, breeding an affected
horse (MCOA or Cyst phenotype) with another affected
358 L. S. Andersson et al.: Equine MCOA locus
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could produce a horse with MCOA. Genetic testing for
PMEL17 is of particular use since the Silver coat color can
be confused with similar coat colors and because it is not
possible to detect the mutation on coat colors that do not
express any black pigment or have coat color genes such as
Gray that could mask the Silver phenotype. So far it
remains speculative whether the PMEL17 mutation causes
both the Silver coat color and MCOA syndrome. However,
linkage disequilibrium between the two is complete; if the
phenotypes are regulated by separate mutations, they are a
maximum of 183 kb apart. Because of this, it may be
practically impossible to ﬁnd horses that have recombined
between these loci (i.e., carrying a haplotype with the
Silver mutation but devoid of the mutation causing MCOA
syndrome). On both sides of the MCOA interval, it is less
than 20 kb between the marker deﬁning the interval border
and the markers within the IBD region (18 and 13 kb,
respectively). Thus, additional ﬁne mapping with our
present horse material will not substantially change the size
of the interval. Therefore, future aims include sequencing
the entire genetic interval by next generation, deep
sequencing to identify all candidate mutations in conserved
sequences, and subsequently permitting functional assay
evaluations.
Acknowledgments We thank the personnel at the Animal Genetics
Laboratory of the Department of Animal Breeding and Genetics
(SLU, Uppsala) for their work with paternity testing of horses. We are
grateful to anonymous horse breeders who have provided DNA
samples. Financial support was obtained from the Swedish Research
Council for Environment, Agricultural Sciences and Spatial Planning
(FORMAS) and the Swedish Foundation for Equine Research (SSH)
to GL.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Andersson LS, Juras R, Ramsey DT, Eason-Butler J, Ewart S,
Cothran G, Lindgren G (2008) Equine Multiple Congenital
Ocular Anomalies maps to a 4.9 megabase interval on horse
chromosome 6. BMC Genet 9:88
Benson G (1999) Tandem repeats ﬁnder: a program to analyze DNA
sequences. Nucleic Acids Res 27(2):573–580
Brunberg E, Andersson L, Cothran G, Sandberg K, Mikko S,
Lindgren G (2006) A missense mutation in PMEL17 is
associated with the Silver coat color in the horse. BMC Genet
7:46
Clark LA, Wahl JM, Rees CA, Murphy KE (2006) Retrotransposon
insertion in SILV is responsible for Merle patterning of the
domestic dog. Proc Natl Acad Sci USA 103(5):1376–1381
Corbeel L, Freson K (2008) Rab proteins and Rab-associated
proteins: major actors in the mechanism of protein-trafﬁcking
disorders. Eur J Pediatr 167(7):723–729
Das AV, James J, Bhattacharya S, Imbalzano AN, Antony ML, Hegde
G, Zhao X, Mallya K, Ahmad F, Knudsen E, Ahmad I (2007)
SWI/SNF chromatin remodeling ATPase Brm regulates the
differentiation of early retinal stem cells/progenitors by inﬂu-
encing Brn3b expression and Notch signaling. J Biol Chem
282(48):35187–35201
Dechassa ML, Zhang B, Horowitz-Scherer R, Persinger J, Woodcock
CL, Peterson CL, Bartholomew B (2008) Architecture of the
SWI/SNF–nucleosome complex. Mol Cell Biol 28(19):6010–
6021
Duncan B, Zhao K (2007) HMGA1 mediates the activation of the
CRYAB promoter by BRG1. DNA Cell Biol 26(10):745–752
Ewart SL, Ramsey DT, Xu J, Meyers D (2000) The horse homolog of
congenital aniridia conforms to codominant inheritance. J Hered
91(2):93–98
Grahn BH, Pinard C, Archer S, Bellone R, Forsyth G, Sandmeyer LS
(2008) Congenital ocular anomalies in purebred and crossbred
Rocky and Kentucky Mountain horses in Canada. Can Vet J
49(7):675–681
Hodgkinson CA, Moore KJ, Nakayama A, Steingrı ´msson E, Copeland
NG, Jenkins NA, Arnheiter H (1993) Mutations at the mouse
microphthalmia locus are associated with defects in a gene
encoding a novel basic-helix-loop-helix-zipper protein. Cell
74(2):395–404
Hu R, Sharma SM, Bronisz A, Srinivasan R, Sankar U, Ostrowski MC
(2007) Eos, MITF, and PU.1 recruit corepressors to osteoclast-
speciﬁc genes in committed myeloid progenitors. Mol Cell Biol
27(11):4018–4027
Johnson JL, Rajagopalan KV, Renier WO, Van der Burgt I,
Ruitenbeek W (2002) Isolated sulﬁte oxidase deﬁciency: muta-
tion analysis and DNA-based prenatal diagnosis. Prenat Diagn
22(5):433–436
Karlsson AC, Kerje S, Hallbook F, Jensen P (2009) The Dominant
white mutation in the PMEL17 gene does not cause visual
impairment in chickens. Vet Ophthalmol 12(5):292–298
Kerje S, Sharma P, Gunnarsson U, Kim H, Bagchi S, Fredriksson R,
Schutz K, Jensen P, von Heijne G, Okimoto R, Andersson L
(2004) The Dominant white, Dun and Smoky color variants in
chicken are associated with insertion/deletion polymorphisms in
the PMEL17 gene. Genetics 168(3):1507–1518
Komaromy A, Rowlan JS (2009) Multiple congenital ocular abnor-
malities (MCOA) syndrome in two silver coat colored ponies.
Proc Am Coll Vet Ophthalmol 40:113
Kuehn C, Weikard R (2007) Multiple splice variants within the
bovine silver homologue (SILV) gene affecting coat color in
cattle indicate a function additional to ﬁbril formation in
melanophores. BMC Genomics 8:335
Kwon BS, Halaban R, Ponnazhagan S, Kim K, Chintamaneni C,
Bennett D, Pickard RT (1995) Mouse silver mutation is caused
by a single base insertion in the putative cytoplasmic domain of
Pmel17. Nucleic Acids Res 23(1):154–158
Liu Z, Carvajal M, Carothers Carraway CA, Carraway KL, Pﬂugf-
elder SC (2000) Increased expression of the type 1 growth factor
receptor family in the conjunctival epithelium of patients with
keratoconjunctivitis sicca. Am J Ophthalmol 129(4):472–480
Liu R, Liu H, Chen X, Kirby M, Brown PO, Zhao K (2001)
Regulation of CSF1 promoter by the SWI/SNF-like BAF
complex. Cell 106(3):309–318
Nobukuni Y, Watanabe A, Takeda K, Skarka H, Tachibana M (1996)
Analyses of loss-of-function mutations of the MITF gene suggest
that haploinsufﬁciency is a cause of Waardenburg syndrome type
2A. Am J Hum Genet 59(1):76–83
L. S. Andersson et al.: Equine MCOA locus 359
123Ramsey DT, Ewart SL, Render JA, Cook CS, Latimer CA (1999a)
Congenital ocular abnormalities of Rocky Mountain horses. Vet
Ophthalmol 2(1):47–59
Ramsey DT, Hauptman JG, Petersen-Jones SM (1999b) Corneal
thickness, intraocular pressure, and optical corneal diameter in
Rocky Mountain Horses with cornea globosa or clinically
normal corneas. Am J Vet Res 60(10):1317–1321
Ramsey DT, Mutti DO, Zadnik C, Bullimore MA, Murphy CJ (2000)
Refractive error in Rocky Mountain horses with cornea globosa
and with normal corneas. Invest Ophthalmol Vis Sci 41(4):S135
Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users
and for biologist programmers. Methods Mol Biol 132:365–386
Rudolph JA, Spier SJ, Byrns G, Hoffman EP (1992) Linkage of
hyperkalaemic periodic paralysis in quarter horses to the horse
adult skeletal muscle sodium channel gene. Anim Genet
23(3):241–250
Santschi EM, Purdy AK, Valberg SJ, Vrotsos PD, Kaese H,
Mickelson JR (1998) Endothelin receptor B polymorphism
associated with lethal white foal syndrome in horses. Mamm
Genome 9(4):306–309
Schonthaler HB, Lampert JM, von Lintig J, Schwarz H, Geisler R,
Neuhauss SC (2005) A mutation in the silver gene leads to
defects in melanosome biogenesis and alterations in the visual
system in the zebraﬁsh mutant fading vision. Dev Biol
284(2):421–436
Shin EK, Perryman LE, Meek K (1997) A kinase-negative mutation
of DNA-PK(CS) in equine SCID results in defective coding and
signal joint formation. J Immunol 158(8):3565–3569
Theos AC, Truschel ST, Raposo G, Marks MS (2005) The Silver
locus product Pmel17/gp100/Silv/ME20: controversial in name
and in function. Pigment Cell Res 18(5):322–336
Thierry-Mieg D, Thierry-Mieg J (2006) AceView: a comprehensive
cDNA-supported gene and transcripts annotation. Genome Biol
7 Suppl 1:S12.1–14
Tryon RC, White SD, Bannasch DL (2007) Homozygosity mapping
approach identiﬁes a missense mutation in equine cyclophilin B
(PPIB) associated with HERDA in the American Quarter Horse.
Genomics 90(1):93–102
Wade CM, Giulotto E, Sigurdsson S, Zoli M, Gnerre S, Imsland F,
Lear TL, Adelson DL, Bailey E, Bellone RR, Blocker H, Distl O,
Edgar RC, Garber M, Leeb T, Mauceli E, MacLeod JN, Penedo
MC, Raison JM, Sharpe T, Vogel J, Andersson L, Antczak DF,
Biagi T, Binns MM, Chowdhary BP, Coleman SJ, Della Valle G,
Fryc S, Guerin G, Hasegawa T, Hill EW, Jurka J, Kiialainen A,
Lindgren G, Liu J, Magnani E, Mickelson JR, Murray J,
Nergadze SG, Onofrio R, Pedroni S, Piras MF, Raudsepp T,
Rocchi M, Roed KH, Ryder OA, Searle S, Skow L, Swinburne
JE, Syvanen AC, Tozaki T, Valberg SJ, Vaudin M, White JR,
Zody MC, Lander ES, Lindblad-Toh K (2009) Genome
sequence, comparative analysis, and population genetics of the
domestic horse. Science 326(5954):865–867
Wang L, Wormstone IM, Reddan JR, Duncan G (2005) Growth factor
receptor signalling in human lens cells: role of the calcium store.
Exp Eye Res 80(6):885–895
Watanabe A, Takeda K, Ploplis B, Tachibana M (1998) Epistatic
relationship between Waardenburg syndrome genes MITF and
PAX3. Nat Genet 18(3):283–286
360 L. S. Andersson et al.: Equine MCOA locus
123